Article
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Antimicrobial agents and chemotherapy - 1 Jun 2004
Grossman Zehava, Paxinos Ellen E, Averbuch Diana, Maayan Shlomo, Parkin Neil T, Engelhard Dan, Lorber Margalit, Istomin Valery, Shaked Yael, Mendelson Ella, Ram Daniela, Petropoulos Chris J, Schapiro Jonathan M
Abstract excerpt
Differences in baseline polymorphisms between subtypes may result in development of diverse mutational pathways during antiretroviral treatment. We compared drug resistance in patients with human immunodeficiency virus subtype C (referred to herein as "subtype-C-infected patients") versus subtype-B-infected patients following protease inhibitor (PI) therapy. Genotype, phenotype, and replication capacity...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
